Hospital
Northwest Arkansas Hospitals, LLC
Northwest Arkansas Hospitals, LLC was paid $11.46M by Medicaid between Jan 2018 and Dec 2024, across 276 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 8.1% of everything it billed.
33Billing provider infoNORTHWEST ARKANSAS HOSPITALS, LLC
SPRINGDALE, AR 72764
SPRINGDALE, AR 72764
33aNPI1699726695assigned 05/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.46M
24GClaims791,768
24DCodes billed276
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#7 of 49
Median peer was paid$2.62M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 122,487 | $1.71M | |
| 2019 | 129,151 | $2.14M | |
| 2020 | 97,650 | $1.40M | |
| 2021 | 106,161 | $1.44M | |
| 2022 | 119,859 | $1.76M | |
| 2023 | 120,389 | $1.69M | |
| 2024incomplete | 96,071 | $1.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.1% | 7,773 | 6,480 | $932K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.4% | 24,921 | 6,224 | $848K |
| 80053 | Comprehensive metabolic panel | 6.6% | 53,599 | 42,120 | $762K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 6,778 | 5,693 | $571K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.3% | 13,157 | 11,017 | $380K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.1% | 62,839 | 47,275 | $359K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.3% | 13,035 | 11,538 | $262K |
| 80050 | General health panel | 2.1% | 5,062 | 4,943 | $236K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 14,750 | 11,031 | $232K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.9% | 6,652 | 5,270 | $222K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.9% | 2,015 | 1,703 | $215K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 20,934 | 15,840 | $196K |
264 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 2,466 | $191K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 3,065 | $185K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.6% | 1,348 | $184K |
| 99284 | Emergency room visit (serious) | 1.3% | 7,325 | $150K |
| 86901 | 1.3% | 6,734 | $149K | |
| 87430 | 1.2% | 12,793 | $140K | |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 13,306 | $134K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 2,217 | $133K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 16,248 | $127K |
| 81025 | 1.0% | 17,123 | $117K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,599 | $113K |
| 84484 | <1% | 14,822 | $112K | |
| 97161 | <1% | 2,718 | $112K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,950 | $112K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,946 | $111K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,546 | $100K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,800 | $98K |
| 83690 | <1% | 15,654 | $98K | |
| 83880 | <1% | 4,959 | $94K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,968 | $92K |
| 99285 | Emergency room visit (most serious) | <1% | 5,579 | $90K |
| 93976 | <1% | 1,565 | $83K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 547 | $83K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,468 | $82K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 591 | $77K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 573 | $73K |
| 80061 | Lipid panel | <1% | 7,768 | $67K |
| 87070 | <1% | 5,375 | $66K | |
| 87077 | <1% | 6,971 | $65K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,807 | $65K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,237 | $64K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,657 | $63K |
| 82962 | <1% | 11,912 | $63K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,438 | $61K |
| 85027 | <1% | 10,347 | $61K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 296 | $60K |
| 81001 | <1% | 20,049 | $60K | |
| 80305 | <1% | 4,128 | $58K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,316 | $54K |
| 72100 | <1% | 1,755 | $53K | |
| 87040 | <1% | 7,086 | $53K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,339 | $52K |
| 80306 | <1% | 3,474 | $50K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,871 | $49K |
| 73562 | <1% | 1,792 | $46K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,723 | $46K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,918 | $45K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,062 | $45K |
| 82077 | <1% | 3,619 | $43K | |
| 81003 | <1% | 17,412 | $42K | |
| 73630 | <1% | 1,883 | $41K | |
| 85730 | <1% | 8,467 | $40K | |
| 76801 | <1% | 1,351 | $40K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 686 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,206 | $39K |
| 85610 | <1% | 10,888 | $37K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,847 | $34K |
| 80143 | <1% | 2,445 | $34K | |
| 83605 | <1% | 4,238 | $34K | |
| 73610 | <1% | 1,876 | $33K | |
| 80179 | <1% | 2,405 | $33K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 784 | $32K |
| 73130 | <1% | 1,506 | $31K | |
| 87186 | <1% | 6,279 | $30K | |
| 84702 | <1% | 3,472 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,397 | $30K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,179 | $29K |
| 86900 | <1% | 6,744 | $29K | |
| 84439 | <1% | 3,956 | $29K | |
| 73110 | <1% | 1,431 | $28K | |
| 82565 | <1% | 2,049 | $28K | |
| 80047 | <1% | 1,252 | $28K | |
| 87081 | <1% | 3,751 | $28K | |
| 73030 | <1% | 1,545 | $27K | |
| 70486 | <1% | 229 | $27K | |
| 97001 | <1% | 635 | $25K | |
| 86803 | <1% | 1,637 | $24K | |
| 74018 | <1% | 1,508 | $24K | |
| 87428 | <1% | 964 | $24K | |
| 76830 | Ultrasound, transvaginal | <1% | 544 | $23K |
| 83735 | <1% | 5,667 | $23K | |
| 86403 | <1% | 1,861 | $23K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,521 | $23K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 112 | $22K |
| 93017 | <1% | 1,599 | $22K | |
| 85379 | <1% | 2,612 | $21K | |
| 94760 | <1% | 2,880 | $21K | |
| 86850 | <1% | 5,349 | $21K | |
| 59025 | Fetal non-stress test | <1% | 241 | $20K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 901 | $19K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 2,779 | $19K |
| 94060 | <1% | 721 | $19K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 229 | $19K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 439 | $19K |
| 71020 | <1% | 1,407 | $18K | |
| 86762 | <1% | 1,250 | $18K | |
| 82805 | <1% | 846 | $18K | |
| 87340 | <1% | 1,795 | $17K | |
| 74022 | <1% | 774 | $17K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 105 | $17K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 43 | $16K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,049 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,426 | $16K |
| 86787 | <1% | 1,083 | $15K | |
| 87807 | <1% | 1,281 | $15K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 43 | $14K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 554 | $14K |
| 90715 | <1% | 956 | $14K | |
| 86592 | <1% | 3,172 | $14K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,430 | $13K |
| 84480 | <1% | 1,128 | $13K | |
| 82607 | <1% | 1,199 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 43 | $11K |
| 93971 | <1% | 335 | $11K | |
| 87806 | <1% | 462 | $11K | |
| 80074 | <1% | 236 | $10K | |
| 87210 | <1% | 2,121 | $10K | |
| 97165 | <1% | 290 | $9K | |
| 80076 | <1% | 1,197 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,068 | $9K |
| 73502 | <1% | 432 | $9K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 62 | $9K |
| 95811 | <1% | 145 | $9K | |
| 86140 | <1% | 1,981 | $9K | |
| 94729 | <1% | 656 | $8K | |
| 82951 | <1% | 547 | $8K | |
| 87147 | <1% | 453 | $8K | |
| 82247 | <1% | 1,264 | $8K | |
| 94726 | <1% | 640 | $8K | |
| 82570 | <1% | 2,158 | $7K | |
| 87075 | <1% | 538 | $7K | |
| 82728 | <1% | 619 | $7K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 278 | $7K |
| 72040 | <1% | 307 | $6K | |
| 93458 | <1% | 102 | $6K | |
| 84100 | <1% | 2,524 | $6K | |
| 76642 | <1% | 278 | $6K | |
| 82950 | <1% | 1,040 | $6K | |
| 83540 | <1% | 1,073 | $5K | |
| 73080 | <1% | 347 | $5K | |
| 71010 | <1% | 645 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 30 | $5K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 163 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 32 | $5K |
| 73090 | <1% | 275 | $4K | |
| 82043 | <1% | 1,399 | $4K | |
| 83550 | <1% | 639 | $4K | |
| 96376 | <1% | 939 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 976 | $4K |
| 82248 | <1% | 890 | $4K | |
| 82550 | <1% | 654 | $4K | |
| 73590 | <1% | 134 | $4K | |
| 70498 | <1% | 31 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,423 | $3K |
| 47562 | <1% | 13 | $3K | |
| 82746 | <1% | 270 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,859 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,372 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,087 | $3K |
| 73140 | <1% | 221 | $3K | |
| 97162 | <1% | 50 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,240 | $3K |
| 84156 | <1% | 943 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,969 | $3K |
| 85651 | <1% | 904 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,310 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 423 | $3K |
| 72141 | <1% | 15 | $3K | |
| 93975 | <1% | 34 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,235 | $2K |
| 87205 | <1% | 761 | $2K | |
| 74010 | <1% | 100 | $2K | |
| 82952 | <1% | 461 | $2K | |
| 84550 | <1% | 578 | $2K | |
| 82803 | <1% | 170 | $2K | |
| 86765 | <1% | 131 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 35 | $2K |
| 70496 | <1% | 17 | $2K | |
| 74000 | <1% | 107 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 45 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,102 | $1K |
| 84112 | <1% | 19 | $1K | |
| 87400 | <1% | 143 | $992.11 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 509 | $981.02 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 325 | $961.59 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,834 | $940.81 |
| 84132 | <1% | 117 | $920.89 | |
| 82330 | <1% | 74 | $920.28 | |
| 82150 | <1% | 141 | $918.68 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,031 | $895.14 |
| 0240U | <1% | 62 | $855.78 | |
| 85007 | <1% | 223 | $827.10 | |
| 84703 | <1% | 68 | $818.63 | |
| 77080 | <1% | 13 | $775.40 | |
| 74230 | <1% | 27 | $775.37 | |
| 36600 | <1% | 36 | $736.48 | |
| 71101 | <1% | 28 | $710.25 | |
| 72050 | <1% | 29 | $636.11 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,013 | $632.64 |
| 84481 | <1% | 49 | $621.47 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 887 | $621.16 |
| 87045 | <1% | 75 | $606.15 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 335 | $601.46 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,074 | $601.18 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 17 | $584.44 |
| 87493 | <1% | 28 | $571.45 | |
| 72110 | <1% | 13 | $570.00 | |
| 86038 | <1% | 66 | $523.25 | |
| 92611 | <1% | 13 | $515.57 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $398.07 |
| 82947 | <1% | 106 | $397.60 | |
| 83721 | <1% | 89 | $383.93 | |
| 86780 | <1% | 28 | $380.57 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 30 | $364.00 |
| G0378 | Hospital observation service, per hour | <1% | 1,239 | $343.79 |
| 99152 | <1% | 818 | $320.35 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 24 | $319.79 |
| 72170 | <1% | 31 | $313.74 | |
| 87046 | <1% | 76 | $310.04 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,381 | $287.22 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 19 | $285.26 |
| 76775 | <1% | 14 | $282.00 | |
| 84403 | <1% | 14 | $278.36 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,343 | $264.57 |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 17 | $252.04 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 18 | $227.90 |
| 86431 | <1% | 47 | $180.16 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 89 | $176.61 |
| 86141 | <1% | 14 | $161.01 | |
| 87899 | <1% | 30 | $159.31 | |
| 87209 | <1% | 12 | $155.70 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 278 | $135.32 |
| C1769 | Guide wire | <1% | 140 | $131.65 |
| 82009 | <1% | 26 | $129.20 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 630 | $116.00 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 17 | $104.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 195 | $103.50 |
| 84295 | <1% | 31 | $103.05 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 414 | $88.30 |
| 82140 | <1% | 15 | $87.43 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 45 | $78.63 |
| 87177 | <1% | 12 | $76.26 | |
| 85652 | <1% | 38 | $54.20 | |
| 81000 | <1% | 14 | $36.16 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 50 | $29.70 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 216 | $28.26 |
| 81002 | <1% | 16 | $21.96 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 15 | $10.72 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 70 | $10.38 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 13 | $8.44 |
| 99153 | Mod sedat endo service >5yrs | 0% | 159 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 77 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 14 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 19 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 28 | $0.00 |
| 97035 | 0% | 50 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 15 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,110 | $0.00 |
| 97116 | 0% | 19 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 15 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 16 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 14 | $0.00 |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.